Home › Compare › MARVF vs ABBV
MARVF yields 71428.57% · ABBV yields 3.06%● Live data
📍 MARVF pulled ahead of the other in Year 1
Combined, MARVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MARVF + ABBV for your $10,000?
Marvel Discovery Corp. engages in the acquisition, exploration, and development of mineral properties in Canada. The company has an option to acquire a 100% interest in the Duhamel Property consists of nine mineral claims covering an area of approximately 500 hectares located northwest of the city of the Saguenay, Quebec; the Wicheeda North project comprises 18 claims that covers 4,423.8 hectares situated Northeast of Prince George, British Columbia; and the Blackfly property that includes five claims consisting of 64 unpatented mining claims located in Atikokan, Ontario. It also has an option to acquire a 100% interest in Slip Gold property consists of six claims with 264 claim units situated in Newfoundland; the Victoria/Long Lake comprises five claims with 53 claim units located in Newfoundland; the East Bull property, which includes 16 mineral claims situated in the Deagle, Gaiashk, and Gerow mining district, Ontario; and the Sandy Pond and Baie Verte Line property comprising 335 mineral claims located in the Province of Newfoundland and Labrador, as well as holds interest in Gander South project comprises 14 mineral claims situated in Newfoundland. In addition, Marvel Discovery Corp. has an option to acquire a 100% interest in the Highway North property consists of five contiguous claims totaling 2,573 hectares located in the Athabasca region of Saskatchewan. The company was formerly known as International Montoro Resources Inc. and changed its name to Marvel Discovery Corp. in February 2021. Marvel Discovery Corp. was incorporated in 1987 and is headquartered in Vancouver, Canada.
Full MARVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.